Most people with atopic dermatitis (a type of eczema) are able to control their symptoms by using topical treatments that are applied to the skin. But for some people with severe atopic dermatitis, ...

Sean, a 17-year-old athlete, has struggled with eczema since he was a toddler. Being outdoors in the heat worsens the rash and itch. He is very self conscious about going out with short sleeve shirts ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

(Bloomberg) -- Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less-than-expected benefit in a late-stage trial. After 24 weeks ...

Like people, eczema comes in many colors. It can appear as red patches in lighter skin, and in gray, purple or dark brown patches in people with darker skin. Patches may also be thicker and/or bumpier ...

Nektar Therapeutics Inc (NASDAQ:NKTR) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data from Benzinga Pro. The company released ...

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic ...

LONDON, Sept 4 (Reuters) - Shares in French drugmaker Sanofi (SASY.PA), opens new tab fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for ...